Examining how personality affects medication adherence in chronic myeloid leukemia patients
Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Patients With Chronic Myeloid Leukemia
This study is trying to see how different personality traits affect whether people with chronic myeloid leukemia stick to their medication plan.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 75 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of California, Irvine Academic / other |
| Drugs / interventions | imatinib, dasatinib, bosutinib, nilotinib |
| Locations | 1 site (Orange, California) |
| Trial ID | NCT06229860 on ClinicalTrials.gov |
What this trial studies
This observational pilot study aims to investigate the relationship between personality traits and adherence to tyrosine kinase inhibitor therapy in patients diagnosed with chronic myeloid leukemia (CML). A total of 75 individuals in the chronic phase of CML will be recruited and participate in focused interviews. During these interviews, researchers will assess TKI adherence, personality types, quality of life, and symptom burden using validated questionnaires. Additionally, treatment response data and physician perceptions of adherence will be collected from electronic health records.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have been diagnosed with chronic myeloid leukemia and are currently receiving treatment with specific tyrosine kinase inhibitors.
Not a fit: Patients who are unable to read and speak English or have impaired decisional capacity to consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of how personality influences medication adherence, potentially leading to tailored interventions that improve treatment outcomes for CML patients.
How similar studies have performed: While the specific focus on personality and TKI adherence is novel, previous studies have explored factors influencing medication adherence in cancer patients, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years of age or older * Diagnosed with chronic myeloid leukemia (CML) and in the chronic phase (CML-CP) * Currently being treated with one of four cancer medications - imatinib, dasatinib, bosutinib, or nilotinib * A patient at the UCI Chao Family Comprehensive Cancer Center (CFCCC), or * A member of a patient support group organized by the CML Buster Foundation * Do not meet any of the criteria listed under "Exclusion Requirements" Exclusion Criteria: * Unable to read and speak English * Impaired decisional capacity to consent
Where this trial is running
Orange, California
- Chao Family Comprehensive Cancer Center University of California, Irvine — Orange, California, United States (Recruiting)
Study contacts
- Principal investigator: Mahtab Jafari, Pharm.D — Chao Family Comprehensive Cancer Center
- Study coordinator: Chao Family Comprehensive Cancer Center University of California, Irvine
- Email: ucstudy@uci.edu
- Phone: 1-877-827-8839
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.